Last reviewed · How we verify
EUTHROID-2 (LIOTRIX (T4)
EUTHROID-2 (generic name: LIOTRIX (T4) is a drug developed by PARKE DAVIS. It is currently FDA-approved.
At a glance
| Generic name | LIOTRIX (T4 |
|---|---|
| Sponsor | PARKE DAVIS |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EUTHROID-2 CI brief — competitive landscape report
- EUTHROID-2 updates RSS · CI watch RSS
- PARKE DAVIS portfolio CI
Frequently asked questions about EUTHROID-2
What is EUTHROID-2?
EUTHROID-2 (LIOTRIX (T4) is a pharmaceutical drug developed by PARKE DAVIS.
Who makes EUTHROID-2?
EUTHROID-2 is developed and marketed by PARKE DAVIS (see full PARKE DAVIS pipeline at /company/parke-davis).
What is the generic name of EUTHROID-2?
LIOTRIX (T4 is the generic (nonproprietary) name of EUTHROID-2.
What development phase is EUTHROID-2 in?
EUTHROID-2 is FDA-approved (marketed).
Related
- Manufacturer: PARKE DAVIS — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing